Diet, nutrition and inflammatory bowel disease

Therapy

Volumn 7, Issue 2, 2010, Pages 179-189

  Hou, Jason K ^a   Sellin, Joseph H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Crohn's disease; Curcumin; Defined diet; Diet; Inflammatory bowel disease; Micronutrient; Nutrition; Ulcerative colitis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALUMINUM; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CURCUMIN; CYANOCOBALAMIN; DISACCHARIDE; DOCOSAHEXAENOIC ACID; FLUORIDE; FOLIC ACID; GLUCOCORTICOID; HERBACEOUS AGENT; ICOSAPENTAENOIC ACID; MESALAZINE; MONOSACCHARIDE; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; SELENIUM; SILICON; TITANIUM; TRACE ELEMENT; UNINDEXED DRUG; VITAMIN D; ZINC;

BONE DENSITY; CANCER PREVENTION; CARBOHYDRATE INTAKE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; CYANOCOBALAMIN DEFICIENCY; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FAT INTAKE; FOLIC ACID DEFICIENCY; FOOD COMPOSITION; FRUIT; GENETIC PREDISPOSITION; HUMAN; MEAT; NONHUMAN; NUTRITIONAL DEFICIENCY; OBESITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN CALORIE MALNUTRITION; REMISSION; REVIEW; RISK REDUCTION; THROMBOSIS; ULCERATIVE COLITIS; VEGETABLE; WOUND HEALING IMPAIRMENT;

EID: 77949622391     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.97     Document Type: Review

References (87)

1. Goh J, O'Morain CA: Review article: nutrition and adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 17(3), 307-320 (2003).
2. Dieleman LA, Heizer WD: Nutritional issues in inflammatory bowel disease. Gastroenterol. Clin. North Am. 27(2), 435-451 (1998).
3. Sousa Guerreiro C, Cravo M, Costa AR et al.: A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. Am. J. Gastroenterol. 102(11), 2551-2556 (2007).
4. Gerasimidis K, McGrogan P, Hassan K, Edwards CA: Dietary modifications, nutritional supplements and alternative medicine in paediatric patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27(2), 155-165 (2008).
5. Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F: Milk tolerance in adults with ulcerative colitis. Am. J. Gastroenterol. 89(6), 872-877 (1994).
6. Ginard D, Riera J, Bonet L et al.: Lactose malabsorption in ulcerative colitis. A case-control study. Gastroenterol. Hepatol. 26(8), 469-474 (2003).
7. Mishkin B, Yalovsky M, Mishkin S: Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am. J. Gastroenterol. 92(7), 1148-1153 (1997).
8. Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF: Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut 34(11), 1547-1551 (1993).
9. Hillingsø JG, Kjeldsen J, Schmidt PT et al.: Effects of topical ropivacaine on eicosanoids and neurotransmitters in the rectum of patients with distal ulcerative colitis. Scand. J. Gastroenterol. 37(3), 325-329 (2002).
10. Sharon P, Ligumsky M, Rachmilewitz D, Zor U: Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 75(4), 638-640 (1978).
11. Guerreiro CS, Ferreira P, Tavares L et al.: Fatty acids, IL6, and TNFa polymorphisms: an example of nutrigenetics in Crohn's disease. Am. J. Gastroenterol. 104(9), 2241-2249 (2009).
12. Amre DK, D'Souza S, Morgan K et al.: Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 102(9), 2016-2025 (2007).
13. D'Souza S, Levy E, Mack D et al.: Dietary patterns and risk for Crohn's disease in children. Inflamm. Bowel Dis. 14(3), 367-373 (2008).
14. Persson PG, Ahlbom A, Hellers G: Diet and inflammatory bowel disease: a case-control study. Epidemiology 3(1), 47-52 (1992).
15. Russel MG, Engels LG, Muris JW et al.: 'Modern life' in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur. J. Gastroenterol. Hepatol. 10(3), 243-249 (1998).
16. Hart AR: Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis - a European prospective cohort study. Gut 58, 1577-1579 (2009).
17. Sakamoto N, Kono S, Wakai K et al. Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan: dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm. Bowel Dis. 11(2), 154-163 (2005).
18. Razack R, Seidner DL: Nutrition in inflammatory bowel disease. Curr. Opin. Gastroenterol. 23(4), 400-405 (2007).
19. Shah S: Dietary factors in the modulation of inflammatory bowel disease activity. MedGenMed 9(1), 60 (2007).
20. Cashman KD, Shanahan F: Is nutrition an aetiological factor for inflammatory bowel disease? Eur. J. Gastroenterol. Hepatol. 15(6), 607-613 (2003).
21. Gibson PR, Shepherd SJ: Personal view: food for thought - western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment. Pharmacol. Ther. 21(12), 1399-1409 (2005).
22. Riordan AM, Ruxton CH, Hunter JO: A review of associations between Crohn's disease and consumption of sugars. Eur. J. Clin. Nutr. 52(4), 229-238 (1998).
23. Kirsner JB, Shorter RG: Recent developments in nonspecific inflammatory bowel disease. N. Engl. J. Med. 306(14), 837-848 (1982).
24. Lomer MC, Grainger SL, Ede R et al.: Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17(3), 377-384 (2005).
25. Lerner A: Aluminum is a potential environmental factor for Crohn's disease induction: extended hypothesis. Ann. NY Acad. Sci. 1107, 329-345 (2007).
26. Powell JJ, Harvey RS, Ashwood P, Wolstencroft R, Gershwin ME, Thompson RP: Immune potentiation of ultrafine dietary particles in normal subjects and patients with inflammatory bowel disease. J. Autoimmun. 14(1), 99-105 (2000).
27. Thoree V, Skepper J, Deere H, Pele LC, Thompson RP, Powell JJ: Phenotype of exogenous microparticle-containing pigment cells of the human Peyer's patch in inflamed and normal ileum. Inflamm. Res. 57(8), 374-378 (2008).
28. Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ: Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur. J. Gastroenterol. Hepatol. 13(2), 101-106 (2001).
29. Filippi J, Al-Jaouni R, Wiroth JB, Hébuterne X, Schneider SM: Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm. Bowel Dis. 12(3), 185-191 (2006).
30. Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ: Comprehensive nutritional status in recently diagnosed patients with Inflammatory bowel disease compared with population controls. Eur. J. Clin. Nutr. 54(6), 514-521 (2000).
31. Bernstein CN, Leslie WD, Leboff MS: AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124(3), 795-841 (2003).
32. Loftus EV Jr: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6(6), 506-513 (2004).
33. Noble CL, McCullough J, Ho W et al.: Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27(7), 588-596 (2008).
34. Naderi N, Farnood A, Habibi M et al.: Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 23(12), 1816-1822 (2008).
35. Pluskiewicz W, Zdrzalek J, Karasek D: Spine bone mineral density and VDR polymorphism in subjects with ulcerative colitis. J. Bone Miner. Metab. 27(5), 567-573 (2009).
36. Kuwabara A, Tanaka K, Tsugawa N et al.: High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 20(6), 935-942 (2009).
37. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK: Inflammatory bowel disease and the risk of fracture. Gastroenterology 125(6), 1591-1597 (2003).
38. Jahnsen J, Falch JA, Mowinckel P, Aadland E: Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37(2), 192-199 (2002).
39. Leslie WD, Miller N, Rogala L, Bernstein CN: Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am. J. Gastroenterol. 103(6), 1451-1459 (2008).
40. von Tirpitz C, Klaus J, Brückel J et al.: Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 12(1), 19-24 (2000).
41. Siffledeen JS, Fedorak RN, Siminoski K et al.: Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin. Gastroenterol. Hepatol. 3(2), 122-132 (2005).
42. Kitazaki S, Mitsuyama K, Masuda J et al.: Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 29(4), 424-430 (2009).
43. Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP: Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J. Am. Diet. Assoc. 107(9), 1575-1580 (2007).
44. Pironi L, Cornia GL, Ursitti MA et al.: Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int. J. Clin. Pharmacol. Res. 8(2), 143-148 (1988).
45. Chiarello PG, Penaforte FR, Japur CC, Souza CD, Vannucchi H, Troncon LE: Increased folate intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases. Dig. Dis. Sci. 54(3), 627-633 (2009).
46. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB: Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 97(2), 255-259 (1989).
47. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112(1), 29-32 (1997).
48. Rannem T, Ladefoged K, Hylander E, Hegnhøj J, Jarnum S: Selenium status in patients with Crohn's disease. Am. J. Clin. Nutr. 56(5), 933-937 (1992).
49. Ringstad J, Kildebo S, Thomassen Y: Serum selenium, copper, and zinc concentrations in Crohn's disease and ulcerative colitis. Scand. J. Gastroenterol. 28(7), 605-608 (1993).
50. Fernández-Bañares F, Mingorance MD, Esteve M et al.: Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status. Am. J. Gastroenterol. 85(12), 1584-1589 (1990).
51. McClain C, Soutor C, Zieve L: Zinc deficiency: a complication of Crohn's disease. Gastroenterology 78(2), 272-279 (1980).
52. Matsui T: Zinc deficiency in Crohn's disease. J. Gastroenterol. 33(6), 924-925 (1998).
53. El-Tawil AM: Zinc deficiency in men with Crohn's disease may contribute to poor sperm function and male infertility. Andrologia 35(6), 337-341 (2003).
54. Tirosh O, Levy E, Reifen R: High selenium diet protects against TNBS-induced acute inflammation, mitochondrial dysfunction, and secondary necrosis in rat colon. Nutrition 23(11-12), 878-886 (2007).
55. Banning A, Florian S, Deubel S et al.: GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells. Antioxid. Redox Signal. 10(9), 1491-1500 (2008).
56. Ballegaard M, Bjergstrøm A, Brøndum S, Hylander E, Jensen L, Ladefoged K: Self-reported food intolerance in chronic inflammatory bowel disease. Scand. J. Gastroenterol. 32(6), 569-571 (1997).
57. Zachos M, Tondeur M, Griffiths AM: Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. (1), CD000542 (2007).
58. Bamba T, Shimoyama T, Sasaki M et al.: Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur. J. Gastroenterol. Hepatol. 15(2), 151-157 (2003).
59. Sakurai T, Matsui T, Yao T et al.: Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. J. Parenter. Enteral. Nutr. 26(2), 98-103 (2002).
60. Leiper K, Woolner J, Mullan MM et al.: A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut 49(6), 790-794 (2001).
61. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. 334(24), 1557-1560 (1996).
62. Lorenz-Meyer H, Bauer P, Nicolay C et al.: Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand. J. Gastroenterol. 31(8), 778-785 (1996).
63. Feagan BG, Sandborn WJ, Mittmann U et al.: Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 299(14), 1690-1697 (2008).
64. Turner D, Zlotkin SH, Shah PS, Griffiths AM: Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. (1), CD006320 (2009).
65. Turner D, Steinhart AH, Griffiths AM: Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. (3), CD006443 (2007).
66. Galvez J, Rodríguez-Cabezas ME, Zarzuelo A: Effects of dietary fiber on inflammatory bowel disease. Mol. Nutr. Food Res. 49(6), 601-608 (2005).
67. Scheppach W, Sommer H, Kirchner T et al.: Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103(1), 51-56 (1992).
68. Breuer RI, Buto SK, Christ ML et al.: Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig. Dis. Sci. 36(2), 185-187 (1991).
69. Hallert C, Björck I, Nyman M, Pousette A, Grännö C, Svensson H: Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm. Bowel Dis. 9(2), 116-121 (2003).
70. Kanauchi O, Suga T, Tochihara M et al.: Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. 37(Suppl. 14), 67-72 (2002).
71. Gottschall E. Breaking the Vicious Cycle: Intestinal Health Through Diet (Revised Edition). Kirkton Press, Ontario, Canada (1994).
72. Rubin JS. The Maker's Diet. Penguin Group (USA), NY, USA (2004).
73. Langhorst J, Anthonisen IB, Steder-Neukamm U et al.: Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm. Bowel Dis. 11(3), 287-295 (2005).
74. Rahimi R, Mozaffari S, Abdollahi M: On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig. Dis. Sci. 54(3), 471-480 (2009).
75. Singh S, Aggarwal BB: Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270(42), 24995-25000 (1995).
76. Holt PR, Katz S, Kirshoff R: Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 50(11), 2191-2193 (2005).
77. Hanai H, Iida T, Takeuchi K et al.: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4(12), 1502-1506 (2006).
78. Hennessee O, Cook W: Aloe Myth, Magic and Medicine: Aloe Vera Across Time. Universal Graphics, PA, USA (1989).
79. Langmead L, Feakins RM, Goldthorpe S et al.: Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment. Pharmacol. Ther. 19(7), 739-747 (2004).
80. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E: Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand. J. Gastroenterol. 37(4), 444-449 (2002).
81. Greenfield SM, Green AT, Teare JP et al.: A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment. Pharmacol. Ther. 7(2), 159-166 (1993).
82. Gupta I, Parihar A, Malhotra P et al.: Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 2(1), 37-43 (1997).
83. Omer B, Krebs S, Omer H, Noor TO: Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14(2-3), 87-95 (2007).
84. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R: Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol. 39(1), 11-17 (2001).
85. Ren J, Tao Q, Wang X, Wang Z, Li J: Efficacy of T2 in active Crohn's disease: a prospective study report. Dig. Dis. Sci. 52(8), 1790-1797 (2007).
86. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK: Chios mastic treatment of patients with active Crohn's disease. World J. Gastroenterol. 13(5), 748-753 (2007).
87. Champe P, Harvey R: Lippincott's Illustrated Reviews: Biochemistry (2nd Edition). Lippincott-Raven Publishers Inc., PA, USA (1994).